论文部分内容阅读
目的观察分析早发型重度子痫前期并胎儿生长受限(FGR)产妇接受期待治疗获得妊娠结局的影响。方法 96例早发型重度子痫前期患者,根据是否合并FGR将患者分为对照组(合并FGR,32例)和观察组(未合并FGR,64例),两组患者均接受期待治疗。对比两组的孕妇分娩孕周、新生儿出生体重、围生儿死亡率。结果所有的孕妇孕周延长了0.1~5.2周,平均延迟1.5周。对照组孕妇分娩孕周为(32.5±1.3)周,新生儿出生体重为(1295.51±309.14)g,围生儿死亡率为15.6%(5/32);观察组孕妇分娩孕周为(31.4±1.5)周,新生儿出生体重为(1600.12±394.42)g,围生儿死亡率为0(0/64)。对照组孕妇分娩孕周晚于观察组,新生儿出生体重低于观察组,围生儿死亡率高于观察组,差异均具有统计学意义(P<0.05)。结论期待治疗并不会增加孕产妇并发症的发生,以上看出合并FGR组的新生儿的心脏发育不全率以及新生儿围生期的死亡率明显比未合并FGR组的高,但是因为期待治疗会延长孕周,从而改善患儿的结局,这也为早发型重度子痫合并FGR期待治疗患者提供了一个临床依据。
Objective To observe and analyze the effect of expectant expectant pregnancy outcome in early onset severe preeclampsia and fetal growth restriction (FGR). Methods 96 patients with early-onset severe preeclampsia were divided into control group (FGR: 32 cases) and observation group (FGR: 64 cases without FGR) according to whether or not FGR was combined. Both groups were treated with expectant treatment. Pregnancy compared gestational age of two groups of pregnant women, newborn birth weight, perinatal mortality. Results All pregnant women extended gestational age from 0.1 to 5.2 weeks with an average delay of 1.5 weeks. The gestational age of pregnant women in the control group was (32.5 ± 1.3) weeks, the newborn birth weight was (1295.51 ± 309.14) g and the perinatal mortality rate was 15.6% (5/32). The gestational age of pregnant women in the observation group was (31.4 ± 1.5) weeks, the newborn birth weight (1600.12 ± 394.42) g, perinatal mortality rate was 0 (0/64). The gestational age of pregnant women in the control group was delayed in the observation group, the newborn birth weight was lower than that of the observation group, and the perinatal mortality rate was higher than that of the observation group. The difference was statistically significant (P <0.05). Conclusion expectant treatment does not increase the incidence of maternal complications, the above shows that newborns with FGR group hypoplasia and neonatal perinatal mortality was significantly higher than those without FGR group, but because of waiting for treatment Will extend the gestational age, thus improving the outcome of children, which also provides a clinical basis for early-onset severe eclampsia patients with FGR expectant treatment.